(Q46743856)

24 December 2017

title

Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity (English)

1 reference

24 December 2017

1 reference

6

Vincent Soriano

1 reference

24 December 2017

author name string

Matilde Sánchez-Conde

1

1 reference

24 December 2017

Carmen de Mendoza

2

1 reference

24 December 2017

Inmaculada Jiménez-Nacher

3

1 reference

24 December 2017

Pablo Barreiro

4

1 reference

24 December 2017

Juan Gonzalez-Lahoz

5

1 reference

24 December 2017

publication date

1 July 2005

1 reference

24 December 2017

published in

HIV Clinical Trials

1 reference

24 December 2017

volume

6

1 reference

24 December 2017

issue

4

1 reference

24 December 2017

page(s)

197-202

1 reference

24 December 2017

Stavudine: an update of its use in the treatment of HIV infection

cites work

1 reference

https://api.crossref.org/works/10.1310%2FED57-EU48-RK6A-E5U0

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FED57-EU48-RK6A-E5U0

Stavudine versus zidovudine and the development of lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FED57-EU48-RK6A-E5U0

Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FED57-EU48-RK6A-E5U0

Lactic acidosis associated with stavudine administration: a report of five cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FED57-EU48-RK6A-E5U0

Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FED57-EU48-RK6A-E5U0

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FED57-EU48-RK6A-E5U0

Evolution of lipid abnormalities in patients switched from stavudine- to tenofovir-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FED57-EU48-RK6A-E5U0

Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FED57-EU48-RK6A-E5U0

Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FED57-EU48-RK6A-E5U0

Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FED57-EU48-RK6A-E5U0

Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FED57-EU48-RK6A-E5U0

The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FED57-EU48-RK6A-E5U0

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FED57-EU48-RK6A-E5U0

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FED57-EU48-RK6A-E5U0

Biologic effects and safety of stavudine: overview of phase I and II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FED57-EU48-RK6A-E5U0

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FED57-EU48-RK6A-E5U0

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FED57-EU48-RK6A-E5U0

A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FED57-EU48-RK6A-E5U0

10.1310/ED57-EU48-RK6A-E5U0

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017